Page 14 - Slide 1

Amgen Bone Health Mentoring Program

Monday, October 15, at 11:30am – 2:30pm ◼ Ruth Chris, Minneapolis, MN

FR0392 Odanacatib Improved Estimated Femoral
Strength in Postmenopausal Women - Results of a 2-
year Placebo-controlled Trial.
Keaveny T, Brixen K, Chapurlat R, et al.
Session: Welcome Reception and Plenary Poster
Session ◼ Friday , October 12, 05:45 PM - 07:00 PM ◼
Discovery Hall-Hall B/Minneapolis Convention Center

Objective Abstract Information Additional Notes from
Methods Poster/Presentation*
▪ This study assessed the effects of ODN on
femoral strength and geometry by QCT in Strengths, Weaknesses,
postmenopausal women. Key Points

▪ This phase-3 trial included 214
postmenopausal women with mean BMD T-
scores of -1.8 at the lumbar spine and
femoral neck

▪ Hip QCT scans at 2 years were available
for a subset of these women (n=129)

▪ FEA was used to assess overall proximal
femoral strength as an exploratory endpoint

▪ QCT was used to assess BMD, BMC and
volume of the integral, cortical and
trabecular compartments

▪ A global vBMD threshold was used to
estimate periosteal and endosteal
boundaries.

* Assignment notes will be collected at the Amgen Mentoring Program Debrief Meeting. Hardcopy or Electronic versions are acceptable